Diabetes, Vol 48, Issue 2 254-260, Copyright © 1999 by American Diabetes Association

ARTICLES

Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma

M Wang, SC Wise, T Leff and TZ Su
Department of Molecular Biology, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, Michigan 48105, USA.

Troglitazone is an antidiabetic agent of the thiazolidinedione family. It is generally believed that thiazolidinediones exert their insulin-sensitizing activity through activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma), a member of the steroid nuclear receptor superfamily. In the present study, we examined the effect of troglitazone on cholesterol biosynthesis in cultured Chinese hamster ovary (CHO) cells. Troglitazone inhibited biosynthesis of cholesterol, but not that of total sterols, in a dose-dependent manner, with a half-maximal concentration (IC50) value of 8 micromol/l. At 20 micromol/l, troglitazone inhibited cholesterol biosynthesis by more than 80%, resulting in the accumulation of lanosterol and several other sterol products. This inhibitory effect observed in CHO cells was also reproduced in HepG2, L6, and 3T3-L1 cells, suggesting that there is a common pathway for this troglitazone action. One hour after removal of troglitazone from the culture medium, disappearance of the accumulated sterols was accompanied by restored cholesterol synthesis, indicating that those accumulated sterols are precursors of cholesterol. PPAR-gamma reporter assays showed that PPAR-gamma activation by troglitazone was completely blocked by actinomycin D and cycloheximide. In contrast, the inhibition of cholesterol synthesis by troglitazone remained unchanged in the presence of the above compounds, suggesting that this inhibition is mechanistically distinct from the transcriptional regulation by PPAR-gamma. Like troglitazone, two other thiazolidinediones, ciglitazone and englitazone, exhibited similar inhibitory effect on cholesterol synthesis; however, other known PPAR-gamma ligands such as BRL49653, pioglitazone, and 15-deoxy-delta(12,14)-prostaglandin J2 showed only weak or no inhibition. The dissociation of PPAR-gamma binding ability from the potency for inhibition of cholesterol synthesis further supports the conclusion that inhibition of cholesterol biosynthesis by troglitazone is unlikely to be mediated by PPAR-gamma.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Grommes, G. E. Landreth, M. Sastre, M. Beck, D. L. Feinstein, A. H. Jacobs, U. Schlegel, and M. T. Heneka Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor {gamma} Agonist Treatment Mol. Pharmacol., November 1, 2006; 70(5): 1524 - 1533. [Abstract] [Full Text] [PDF]

				S.-H. Jo, C. Yang, Q. Miao, M. Marzec, M. A. Wasik, P. Lu, and Y. L. Wang Peroxisome Proliferator-Activated Receptor {gamma} Promotes Lymphocyte Survival through Its Actions on Cellular Metabolic Activities J. Immunol., September 15, 2006; 177(6): 3737 - 3745. [Abstract] [Full Text] [PDF]

				A. Klopotek, F. Hirche, and K. Eder PPAR{gamma} Ligand Troglitazone Lowers Cholesterol Synthesis in HepG2 and Caco-2 Cells via a Reduced Concentration of Nuclear SREBP-2 Experimental Biology and Medicine, September 1, 2006; 231(8): 1365 - 1372. [Abstract] [Full Text] [PDF]

				R. Pasquali and A. Gambineri Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775. [Abstract] [Full Text] [PDF]

				C. E Minge, N. K. Ryan, K. H. V. D. Hoek, R. L. Robker, and R. J. Norman Troglitazone Regulates Peroxisome Proliferator-Activated Receptors and Inducible Nitric Oxide Synthase in Murine Ovarian Macrophages Biol Reprod, January 1, 2006; 74(1): 153 - 160. [Abstract] [Full Text] [PDF]

				C. J. Thompson, S. M. Ross, J. Hensley, K. Liu, S. C. Heinze, S. S. Young, and K. W. Gaido Differential Steroidogenic Gene Expression in the Fetal Adrenal Gland Versus the Testis and Rapid and Dynamic Response of the Fetal Testis to Di(n-butyl) Phthalate Biol Reprod, November 1, 2005; 73(5): 908 - 917. [Abstract] [Full Text] [PDF]

				A. M. Schwab, S. Granholm, E. Persson, B. Wilkes, U. H. Lerner, and H. H. Conaway Stimulation of Resorption in Cultured Mouse Calvarial Bones by Thiazolidinediones Endocrinology, October 1, 2005; 146(10): 4349 - 4361. [Abstract] [Full Text] [PDF]

				J. Lu, K. Imamura, S. Nomura, K.-i. Mafune, A. Nakajima, T. Kadowaki, N. Kubota, Y. Terauchi, G. Ishii, A. Ochiai, et al. Chemopreventive Effect of Peroxisome Proliferator-Activated Receptor {gamma} on Gastric Carcinogenesis in Mice Cancer Res., June 1, 2005; 65(11): 4769 - 4774. [Abstract] [Full Text] [PDF]

				R. Oliver III, E. Friday, F. Turturro, A. Lacy, and T. Welbourne Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: physiological responses Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1257 - F1266. [Abstract] [Full Text] [PDF]

				G. Llaverias, M. Vazquez-Carrera, R. M. Sanchez, V. Noe, C. J. Ciudad, J. C. Laguna, and M. Alegret Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism J. Lipid Res., November 1, 2004; 45(11): 2015 - 2024. [Abstract] [Full Text] [PDF]

				S. J. Baek, J.-S. Kim, J. B. Nixon, R. P. DiAugustine, and T. E. Eling Expression of NAG-1, a Transforming Growth Factor-{beta} Superfamily Member, by Troglitazone Requires the Early Growth Response Gene EGR-1 J. Biol. Chem., February 20, 2004; 279(8): 6883 - 6892. [Abstract] [Full Text] [PDF]

				T. Kumagai, T. Ikezoe, D. Gui, J. O'Kelly, X.-J. Tong, F. J. Cohen, J. W. Said, and H. P. Koeffler RWJ-241947 (MCC-555), A Unique Peroxisome Proliferator-Activated Receptor-{gamma} Ligand with Antitumor Activity against Human Prostate Cancer in Vitro and in Beige/Nude/ X-Linked Immunodeficient Mice and Enhancement of Apoptosis in Myeloma Cells Induced by Arsenic Trioxide Clin. Cancer Res., February 15, 2004; 10(4): 1508 - 1520. [Abstract] [Full Text] [PDF]

				T. Welbourne, E. Friday, R. Fowler, F. Turturro, and I. Nissim Troglitazone acts by PPAR{gamma} and PPAR{gamma}-independent pathways on LLC-PK1-F+ acid-base metabolism Am J Physiol Renal Physiol, January 1, 2004; 286(1): F100 - F110. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				P. Misra, R. Chakrabarti, R. K. Vikramadithyan, G. Bolusu, S. Juluri, J. Hiriyan, C. Gershome, A. Rajjak, P. Kashireddy, S. Yu, et al. PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor {gamma} Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 763 - 771. [Abstract] [Full Text] [PDF]

				S. J. Baek, L. C. Wilson, L. C. Hsi, and T. E. Eling Troglitazone, a Peroxisome Proliferator-activated Receptor gamma (PPARgamma ) Ligand, Selectively Induces the Early Growth Response-1 Gene Independently of PPARgamma . A NOVEL MECHANISM FOR ITS ANTI-TUMORIGENIC ACTIVITY J. Biol. Chem., February 14, 2003; 278(8): 5845 - 5853. [Abstract] [Full Text] [PDF]

				H. P. Koeffler Peroxisome Proliferator-activated Receptor {gamma} and Cancers Clin. Cancer Res., January 1, 2003; 9(1): 1 - 9. [Abstract] [Full Text] [PDF]

				C. E. Clay, A. Monjazeb, J. Thorburn, F. H. Chilton, and K. P. High 15-Deoxy-{Delta}12,14-prostaglandin J2-induced apoptosis does not require PPAR{gamma} in breast cancer cells J. Lipid Res., November 1, 2002; 43(11): 1818 - 1828. [Abstract] [Full Text] [PDF]

				E. Cernuda-Morollon, F. Rodriguez-Pascual, P. Klatt, S. Lamas, and D. Perez-Sala PPAR Agonists Amplify iNOS Expression While Inhibiting NF-{kappa}B: Implications for Mesangial Cell Activation by Cytokines J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2223 - 2231. [Abstract] [Full Text] [PDF]

				Y. L. Wang, K. A. Frauwirth, S. M. Rangwala, M. A. Lazar, and C. B. Thompson Thiazolidinedione Activation of Peroxisome Proliferator-activated Receptor gamma Can Enhance Mitochondrial Potential and Promote Cell Survival J. Biol. Chem., August 23, 2002; 277(35): 31781 - 31788. [Abstract] [Full Text] [PDF]

				L. G. D. Fryer, A. Parbu-Patel, and D. Carling The Anti-diabetic Drugs Rosiglitazone and Metformin Stimulate AMP-activated Protein Kinase through Distinct Signaling Pathways J. Biol. Chem., July 5, 2002; 277(28): 25226 - 25232. [Abstract] [Full Text] [PDF]

				M. F. M. Mitwally, S. F. Witchel, and R. F. Casper Troglitazone: A Possible Modulator of Ovarian Steroidogenesis Reproductive Sciences, May 1, 2002; 9(3): 163 - 167. [Abstract] [PDF]

				M. Fu, J. Zhang, X. Zhu, D. E. Myles, T. M. Willson, X. Liu, and Y. E. Chen Peroxisome Proliferator-activated Receptor gamma Inhibits Transforming Growth Factor beta -induced Connective Tissue Growth Factor Expression in Human Aortic Smooth Muscle Cells by Interfering with Smad3 J. Biol. Chem., November 30, 2001; 276(49): 45888 - 45894. [Abstract] [Full Text] [PDF]

				B. Brunmair, F. Gras, S. Neschen, M. Roden, L. Wagner, W. Waldhausl, and C. Furnsinn Direct Thiazolidinedione Action on Isolated Rat Skeletal Muscle Fuel Handling Is Independent of Peroxisome Proliferator-Activated Receptor-{gamma}-Mediated Changes in Gene Expression Diabetes, October 1, 2001; 50(10): 2309 - 2315. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				W. T. Schaiff, M. G. Carlson, S. D. Smith, R. Levy, D. M. Nelson, and Y. Sadovsky Peroxisome Proliferator-Activated Receptor-{gamma} Modulates Differentiation of Human Trophoblast in a Ligand-Specific Manner J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3874 - 3881. [Abstract] [Full Text]

				C. Fürnsinn, B. Brunmair, S. Neschen, M. Roden, and W. Waldhäusl Troglitazone Directly Inhibits CO2 Production from Glucose and Palmitate in Isolated Rat Skeletal Muscle J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 487 - 493. [Abstract] [Full Text]

				R. E. Law, S. Goetze, X.-P. Xi, S. Jackson, Y. Kawano, L. Demer, M. C. Fishbein, W. P. Meehan, and W. A. Hsueh Expression and Function of PPAR{gamma} in Rat and Human Vascular Smooth Muscle Cells Circulation, March 21, 2000; 101(11): 1311 - 1318. [Abstract] [Full Text] [PDF]

				J. G. Hunter, M. F. van Delft, R. A. Rachubinski, and J. P. Capone Peroxisome Proliferator-activated Receptor gamma Ligands Differentially Modulate Muscle Cell Differentiation and MyoD Gene Expression via Peroxisome Proliferator-activated Receptor gamma -dependent and -independent Pathways J. Biol. Chem., October 5, 2001; 276(41): 38297 - 38306. [Abstract] [Full Text] [PDF]